iwWM 2022 – Steven P. Treon
Steven P. Treon explains where we are at present regarding curability of Waldenström‘s Macroglobulinemia, key questions in the management of patients with WM, genomic testing and genomically driven algorithms for the treatment of WM. Moreover, he discusses which treatments might be implemented in the future while finally summarizing his highlights from the 11th International Workshop on WM.
Here is the full iwWM 2022 report.
More posts
Emergent BTKi treatments in WM
Additionally to ibrutinib, to date the only once-daily BTK inhibitor approved in the USA and the European Union either as monotherapy or in combination with RTX for patients with WM [1], other BTKis, such as acalabrutinib and zanubrutinib, are now emerging as potential therapeutic alternatives. Acalabrutinib is an emergent, potent, and selective BTKi, which has received accelerated approval by the US FDA for the treatment of adult patients with relapsed or refractory (R/R) MCL and is in clinical development for CLL and DLBCL.
BTK inhibition in Waldenström’s macroglobulinemia: trial updates and biomarker analysis
The open-label, multicenter, randomized phase III ASPEN trial was set up to assess the efficacy and safety of the potent, selective, irreversible next-generation BTK inhibitor zanubrutinib in Waldenström’s macroglobulinemia (WM). Cohort 1 of the study included patients with MYD88-mutated disease (n = 201); here, zanubrutinib was compared to ibrutinib after 1:1 randomization.
Management of WM patients previously exposed to BTK-inhibitors
Many patients with WM require continuous treatment with BTK inhibitors, but difficult-to-manage AEs often lead to treatment discontinuation. Zanubrutinib is a potent and selective next-generation BTKi designed to minimize off-target kinase binding and associated side effects.
New insights into BTKi treatment of Waldenström‘s macroglobulinemia
Waldenström’s macroglobulinemia (WM) is a low-grade non-Hodgkin B-cell lymphoplasmacytic lymphoma, characterized by the accumulation of clonal lymphoplasmacytic cells secreting monoclonal IgM protein in the bone marrow and other organs. WM is a lymphoma accounting for only 1–2 % of all hematologic tumors, with an annual incidence of three to four cases per million people in the USA and Europe, classifying it as a rare disease.
Preface – iwWM 2022
The 11th International Workshop on Waldenström’s Macroglobulinemia (iwWM), held in Madrid, Spain, and virtually from 27th–30th October 2022, featured 20 sessions with more than 100 presentations.